Study | Study characteristics | Group | N | Male (n) | GA (wk) | BW (g) | Antenatal glucocorticoid | RDS (n) | Surfactant(n) |
---|---|---|---|---|---|---|---|---|---|
AACs vs placebo | |||||||||
Arnon [35] 1996 | 1 centre UK | T C | 15 15 | NA NA | 27.5 (0.7)a 27.1 (0.89)a | 1024 (92.3)a 1041 (113)a | 7 (46.7%) 8 (53.3%) | NA NA | NA NA |
Bassler [16] 2015 | 10 centres Switzerland | T C | 437 419 | NA NA | 26.1 (1.3)a 26.1 (1.2)a | 798 (193)a 803 (189)a | 388 (88.8%) 383 (91.4%) | NA NA | NA NA |
Cao [36] 2016 | 1 centre China | T C | 40 40 | NA NA | 30.1 (2.2)a 30.7 (1.8)a | 1333 (110)a 1339 (105)a | NA NA | 40 40 | 40 40 |
Cole [37] 1999 | 4 centres USA | T C | 123 130 | 51 53 | 26 (2)a 26 (2)a | 800 (193)a 802 (189)a | 77 (62.6%) 68 (52.3%) | 123 129 | 95 97 |
Denjean [38] 1998 | 6 centres France | T C | 43 43 | 26 26 | 27.6 (1.5)a 27.8 (1.6)a | 1060 (218)a 1082 (260)a | 11 (25.6%) 11 (25.6%) | 43 43 | 31 34 |
Fok [39] 1999 | 1 centre Hong Kong | T C | 27 26 | NA NA | 27.9 (0.5)a 27.1 (0.5)a | 993 (71)a 981 (71)a | 15 (55.6%) 13 (50.0%) | NA NA | NA NA |
Giep [40] 1996 | 1 centre USA | T C | 10 9 | 6 3 | 26 (2.0)a 25 (1.6)a | 752 (110)a 784 (141)a | 4 (40.0%) 2 (22.2%) | 8 9 | 8 9 |
Jangaard [41] 2002 | 1 centre Germany | T C | 30 30 | 13 13 | 27.2 (2)a 27.9 (2)a | 882 (204)a 917 (178)b | 15 (50.0%) 16 (53.3%) | 19 25 | 19 25 |
Jonsson [42] 2000 | 1 centre Sweden | T C | 15 15 | 8 11 | 25 (23,27)b 26 (24,29)b | 766 (525,1122)b 813 (630,1227)b | 12 (80.0%) 10 (66.7%) | 14 15 | 14 15 |
Ke [43] 2016 | 1 centre China | T C | 46 46 | 20 27 | <32 <32 | <1500 <1500 | NA NA | 46 46 | 46 46 |
LaForce [44] 1993 | 1 centre USA | T C | 10 11 | NA NA | NA NA | <1500 <1500 | NA NA | NA NA | NA NA |
Merz [45] 1999 | 1 centre Germany | T C | 12 11 | 5 7 | 28 (27,32)b 29 (27,31)b | 1108 (820,1420)b 1120 (880,1480)b | 7 (58.3%) 7 (63.6%) | 12 11 | 10 9 |
Nakamura [24] 2016 | 1 centre Japan | T C | 107 104 | 63 50 | 26 (25,27)b 26 (25,27)b | 783.87 (134.8)b 784.06 (127.2)b | 45 (42.1%) 42 (40.4%) | 90 88 | NA NA |
Pappagallo [46] 1998 | 1 centre USA | T C | 9 9 | 5 5 | 26.8 (1.1)a 26.6 (0.8)a | 828 (64)a 849 (89)a | NA NA | NA NA | NA NA |
Townsend [47] 1998 | 1 centre Denver | T C | 15 17 | 8 8 | 25.8 25.5 | 728 695 | NA NA | 15 17 | NA NA |
Wen [48] 2016 | 1 centre China | T C | 80 80 | 54 51 | 30.5 (2.6)a 31.2 (2.3)a | 1220 (183)a 1250 (167)a | NA NA | NA NA | NA NA |
Yeh [49] 2008 Kuo [50] 2010 | 1 centre Taiwan | T C | 60 56 | 31 29 | 26.4 (2.2)a 26.7 (2.3)a | 881 (245)a 919 (272)a | 46 (76.7%) 42 (75.0%) | 60 56 | 60 56 |
Yeh [25] 2016 | 1 centre Taiwan | T C | 131 134 | NA NA | 26.5 (2.2)a 26.8 (2.2)a | 882 (249)a 935 (283)a | NA NA | 131 134 | 131 134 |
Yong [20] 1999 | 1 centre UK | T C | 20 20 | 13 12 | 27.4 (1.7)a 27.7 (1.7)a | 1011 (223)a 932 (401)a | NA NA | NA NA | NA NA |
Zimmerman [51] 2000 | 1 centre USA | T C | 20 19 | 12 8 | 26 (2.0)a 26 (2.0)a | 910 (198)a 802 (225)a | 14 (70.0%) 15 (78.9%) | 15 18 | 15 18 |
Inhaled corticosteroids vs systemic corticosteroids | |||||||||
Dimitriou [52] 1997 | 1 centre UK | T C | 20 20 | NA NA | 27 (24,30)b 27 (24,31) | 849 (584,1270)b 818 (425,1460)b | 12 (60.0%) 11 (55.0%) | NA NA | 14 12 |
Groneck [53] 1999 | 1 centre Germany | T C | 7 9 | 3 3 | 26 (25,28)b 26 (25,28)b | 800 (500,1020)b 847 (660,1030)b | NA NA | NA NA | NA NA |
Halliday [54] 2001 Wilson [55] 2006 | 47 centre Europe | T C | 285 285 | 142 164 | 27.2 (1.9)a 27.2 (1.9)a | 1002 (281)a 1011 (285)a | 177 (62.1%) 164 (57.5%) | NA NA | 265 260 |
Rozycki [56] 2003 | 1 centre USA | T C | 46 15 | 23 7 | <31 <31 | <1500 <1500 | 6 (13.0%) 2 (13.3%) | 46 15 | 46 15 |
Suchomski [57] 2002 | 1 centre USA | T C | 51 27 | 25 19 | 26 (1.6)a 26 (2.0)a | 844 (157)a 843 (227)a | 34 (66.7%) 16 (59.3%) | NA NA | NA NA |